Jagielski Mateusz
Department of General, Gastroenterological and Oncological Surgery, Nicolaus Copernicus University, Toruń 87-100, Kujawsko-Pomorskie, Poland.
World J Gastrointest Endosc. 2024 Dec 16;16(12):691-693. doi: 10.4253/wjge.v16.i12.691.
First of all, I would like to congratulate Vilas-Boas on an interesting publication. In this letter the authors write about very interesting topics in the management of patients with malignant gastric outlet obstruction (GOO). GOO developed in up to 20% of patients with advanced hepatopancreatobiliary disease both in benign and malignant form. For this reason, the issue is very current. I fully agree with Vilas-Boas that technical aspect of the procedures (surgeon's view) often differs from the patient's view (regarding such factors as cancer-related survival, overall survival, body mass composition, nutritional biomarkers, chemotherapy tolerance and patient-reported quality of life). The mentioned factors should be taken into account when interpreting the effectiveness of treatment modalities for malignant GOO (mGOO), which should be also considered in the future studies in this subject. In my opinion, all above mentioned factors could be summarized in one term: "Improving quality of life of patients with mGOO".
首先，我要祝贺维拉斯 - 博阿斯发表了一篇有趣的文章。在这封信中，作者们探讨了恶性胃出口梗阻（GOO）患者管理中非常有趣的话题。在晚期肝胰胆疾病患者中，高达20%的患者会出现良性或恶性形式的胃出口梗阻。因此，这个问题非常具有时效性。我完全同意维拉斯 - 博阿斯的观点，即手术的技术层面（外科医生的视角）往往与患者的视角不同（涉及癌症相关生存、总生存、身体成分、营养生物标志物、化疗耐受性以及患者报告的生活质量等因素）。在解释恶性胃出口梗阻（mGOO）治疗方式的有效性时应考虑上述因素，这在该主题的未来研究中也应予以考虑。在我看来，所有上述因素可以用一个术语概括：“提高mGOO患者的生活质量”。
